Safety evaluation of TOPAZ-1 and KEYNOTE-966 regimens in metastatic biliary tract cancer: a systematic review and meta-analysis.
Two approved immunotherapy combinations for bile duct cancer differ in specific side effect profiles, helping doctors choose the better option for individual patients.
Systematic meta-analysis establishes comparable overall toxicity but differential specific adverse event profiles for the two approved immunotherapy regimens in metastatic biliary tract cancer. Actionable safety differentiation aids oncologists in individualized treatment selection.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Metastatic biliary tract cancer patients from TOPAZ-1 and KEYNOTE-966 trials
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Clinical & experimental metastasis
Why it surfaced
Systematic review+meta-analysis of approved biliary tract cancer regimens; safety differentiation aids clinical decisions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.